MedPath

Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests

Phase 3
Recruiting
Conditions
Type 2 diabetes mellitus.
Diabetes mellitus due to underlying condition
Registration Number
IRCT20191209045671N3
Lead Sponsor
Semnan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

All type 2 diabetic patients with non-alcoholic fatty liver
Having the consent to participate in the study
Age between 20 to 65 years
Healthy physical status

Exclusion Criteria

history of taking SGLT2 inhibitors
being pregnant for women
history of malignancy and diseases such as AIDS and hepatitis

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.